The technique at the heart of the study is called habitat imaging, and it represents a fundamental shift in how radiologists look at tumors. Instead of treating a tumor as a single lump to be measured with a ruler, habitat imaging divides it into biologically distinct subregions, or habitats, based on the functional characteristics of each voxel, the tiny three-dimensional pixels that make up the scan. The researchers used dynamic contrast-enhanced MRI, or DCE-MRI, which tracks the passage of a gadolinium contrast agent through tissue in real time. By fitting the resulting signal curves to a mathematical framework known as the Tofts model, they extracted pharmacokinetic parameters that describe the tumor’s microvasculature: Ktrans, which reflects the transfer of contrast from blood plasma into tissue; Ve, the volume of the extracellular space; and Kep, the rate at which contrast returns to the blood.

These parameters are not just numbers on a screen. They encode the biology of the tumor microenvironment. A region with high Ktrans is densely vascularized and leaky, often a sign of aggressive growth and abundant blood supply. A region with high Ve may indicate necrosis, edema, or expanded extracellular matrix, all of which can follow effective treatment. When radiation and targeted therapy attack a tumor, they strike these microenvironmental compartments unevenly. Some pockets of cancer cells die quickly as their blood supply collapses; others, perhaps better oxygenated or genetically hardier, survive. Conventional MRI and the widely used RECIST 1.1 criteria, which simply measure the longest diameter of the tumor, are blind to this internal heterogeneity. A tumor can be riddled with dead tissue yet still measure the same size on a standard scan.

To test whether habitat imaging could capture these early changes, the team prospectively enrolled 28 patients with soft tissue sarcoma who were undergoing protocol-specified neoadjuvant radiotherapy-based treatment, an approach combining radiation with targeted therapy. The study was conducted under two prospectively registered clinical trials, NCT05167994 and NCT05938374, and all participants gave written informed consent. Each patient underwent DCE-MRI twice: once at baseline before treatment began, and again six weeks into therapy. After the tumors were surgically removed, an experienced sarcoma pathologist examined the resected specimens and determined the percentage of viable residual tumor cells, the gold-standard measure of how well the treatment had worked.

The pathological results underscored just how difficult this disease is to treat. Only 5 of the 28 patients, or 17.9 percent, achieved a favorable response, defined as 5 percent or fewer viable tumor cells remaining in the surgical specimen. The remaining patients had substantial amounts of surviving cancer despite weeks of radiation and targeted therapy. This imbalance, with so few responders, is itself a reminder of why early prediction matters: if clinicians could identify non-responders early, they might intensify treatment, switch strategies, or spare patients the toxicities of a regimen that is not working.

The imaging analysis began with K-means clustering, an unsupervised machine learning algorithm that groups voxels according to their Ktrans and Ve values. This partitioned each tumor into distinct habitats representing different vascular and tissue microenvironments. The researchers then extracted radiomic features, quantitative descriptors of shape, intensity, and texture, from both the whole tumor and the individual habitat subregions. They also computed delta radiomics features, calculated as the difference between pre-treatment and post-treatment values, capturing how each feature changed over the course of therapy. After univariate analysis identified seven features associated with treatment response, the team built three logistic regression models using Akaike information criterion-based bidirectional selection: a Whole-tumor model, a Habitat model, and a Delta model.

The results were striking, though the researchers are careful to frame them as preliminary. All habitat subregions showed significant volumetric reduction after therapy, with all P values below 0.05, although the proportional shrinkage did not differ significantly among subregions. The standout performer was the Habitat model, which combined two features: pre-treatment Ktrans cluster-1 kurtosis, a measure of how peaked the distribution of vascular permeability values was before treatment, and post-treatment Kep cluster-3 uniformity, which describes how homogeneous the contrast washout rate became in one habitat after therapy. This model achieved an area under the receiver operating characteristic curve of 0.887, with 100 percent sensitivity and 73.9 percent specificity in the apparent analysis. In other words, it caught every true responder while misclassifying roughly a quarter of non-responders as responders.

Bootstrap internal validation tempered the enthusiasm somewhat. After correcting for optimism, the AUC dropped to 0.764, and the corrected discrimination was comparable across the three radiomics-based models. This kind of shrinkage is expected in small studies and is precisely why the authors describe their findings as exploratory. Still, the Habitat model showed favorable calibration, with a Hosmer-Lemeshow P value of 0.973, meaning its predicted probabilities aligned well with observed outcomes, and decision curve analysis suggested potential clinical utility. Perhaps most telling was the comparison with the current standard of care. RECIST 1.1, evaluated as a fixed categorical reference, achieved only 40 percent sensitivity, 82.6 percent specificity, and 75 percent accuracy against the pathological endpoint. The conventional method missed more than half of the patients whose tumors had actually responded, while the habitat-based model caught all of them.

The clinical implications of this work extend well beyond sarcoma. Neoadjuvant therapy is increasingly used across oncology, and the ability to predict pathological response non-invasively, mid-treatment, could transform decision-making for many cancers. In sarcoma specifically, patients who respond well might be candidates for less radical surgery, preserving limbs and function, while non-responders could be escalated to alternative regimens before precious months are lost. The pharmacokinetic parameters underlying the habitat approach are mechanistically meaningful, tied to perfusion, vessel permeability, and cell death, rather than being opaque statistical correlations. That biological grounding gives the method a plausibility that purely data-driven radiomics sometimes lacks, and it offers a window into the tumor microenvironment that no size measurement can provide.

Cautions remain, and the authors are candid about them. Twenty-eight patients is a small sample, the responder group contained only five individuals, and the optimism-corrected performance figures show how much apparent accuracy can evaporate under validation. Treatment protocols were not fully standardized across the cohort, and the models have not yet been tested on external data. The researchers themselves call for validation in larger prospective multicenter cohorts with more balanced response groups and standardized treatment regimens. Yet as a proof of concept, the study is compelling: it demonstrates that the internal architecture of a tumor, read through the lens of DCE-MRI habitat imaging, carries early signals of treatment success that conventional imaging simply cannot see. If larger trials confirm these findings, the six-week MRI scan could become a routine checkpoint in sarcoma care, giving patients and physicians the one thing they currently lack, which is time to change course.

Subject of Research: DCE-MRI-based habitat imaging for early prediction of treatment response in soft tissue sarcoma

Article Title: Longitudinal DCE-MRI-based habitat imaging for early prediction of treatment response to neoadjuvant radiotherapy and targeted therapy in soft tissue sarcoma: a preliminary study

Article References: Jiang, X., Wen, X., Jiang, J., Liu, F., Yang, Z., Miao, L., Li, J., Wang, S., Li, M., & Lu, N. (2026). Longitudinal DCE-MRI-based habitat imaging for early prediction of treatment response to neoadjuvant radiotherapy and targeted therapy in soft tissue sarcoma: a preliminary study. BMC Medical Imaging. https://doi.org/10.1186/s12880-026-02810-5

Image Credits: AI Generated

DOI: 10.1186/s12880-026-02810-5

Keywords: soft tissue sarcoma, DCE-MRI, habitat imaging, radiomics, neoadjuvant radiotherapy, treatment response, Ktrans, Tofts model, RECIST 1.1, pathological response, machine learning, biomarker

Soft tissue sarcomas are a rare and notoriously heterogeneous family of malignancies arising from the body’s mesenchymal tissues—skeletal muscle, fat, fibrous sheaths, blood vessels, and peripheral nerves—collectively accounting for roughly one percent of cancers in adults. Their surgical management is unforgiving. These tumors tend to grow by compressing neighboring structures and sending microscopic extensions along fascial planes, so curative surgery demands wide excision with a cuff of healthy tissue, ideally while preserving the limb’s function. Radiotherapy is added when the risk of local recurrence is high, and the timing of that radiation has become one of the field’s central strategic questions. Delivered before surgery—a strategy known as neoadjuvant radiotherapy—the treatment operates on an intact, well-oxygenated tumor whose full anatomical extent can still be visualized, permitting smaller and more precisely contoured radiation fields than are possible once the surgical bed has been disturbed. Preoperative radiation can also render tumor cells less viable, theoretically reducing the risk of seeding cancer cells during resection, and may shrink bulky lesions enough to convert an amputation into a limb-sparing operation. The trade-offs are real, since wound-healing complications loom larger, and success hinges on disciplined coordination between radiation oncologists and surgeons.

To understand why some physicians embrace this sequence and others hesitate, the researchers turned to the knowledge–attitude–practice framework, a classic construct in health services research that treats clinical behavior as the end product of what clinicians know and what they believe. Between November and December 2023, the team administered an investigator-designed, self-administered questionnaire to specialists recruited from multiple Beijing hospitals through purposive sampling, a technique that deliberately targets respondents with direct experience of the problem under study. The instrument captured baseline characteristics, knowledge, attitudes, and practices concerning neoadjuvant therapy, together with measures of the doctor–patient relationship and the difficulties clinicians perceive in their interactions with patients. Internet Protocol controls were used during questionnaire distribution to prevent duplicate submissions, and the internal consistency of the instrument was verified using Cronbach’s alpha. The study received ethical approval from the review committee of Beijing Jishuitan Hospital and was conducted in accordance with the Declaration of Helsinki, with written informed consent obtained from every participant.

After screening out problematic questionnaires, the analysis settled on 467 valid responses from specialists with a mean age of 42.20 years—an experienced, mid-career cohort that forms the backbone of China’s sarcoma services. Respondents reported a mean doctor–patient relationship score of 22.61, with a standard deviation of 5.62, quantifying the relational climate in which treatment conversations unfold. When the team stratified knowledge, attitude, and practice scores across demographic characteristics, statistically significant differences emerged by department affiliation and by the frequency with which specialists consulted sarcoma patients, with P values below 0.05. In practical terms, a physician’s institutional home and daily caseload—whether one practices within a dedicated bone and soft tissue tumor service or a general orthopedic department, and whether sarcoma patients arrive weekly or only occasionally—leave measurable fingerprints on what doctors know, how they feel, and what they do.

The raw numbers told a strikingly consistent story. Knowledge scores averaged 15.52, with a standard deviation of 2.68, on a scale running from 0 to 18—roughly 86 percent of the theoretical maximum. Attitudes, measured on a possible range of 8 to 40, averaged 34.01, plus or minus 2.87, and practices, on a range of 8 to 30, averaged 26.19, plus or minus 2.99, both again approaching the upper limits of their scales. Taken together, the profile depicts a specialist community that is well informed about neoadjuvant radiotherapy, views it favorably, and reports acting on that conviction in daily clinical work. For a treatment whose adoption has lagged unevenly across health systems worldwide, the documented enthusiasm among Chinese sarcoma specialists is notable, and it provides a rare quantitative baseline for a subspecialty in which practice patterns have been difficult to measure at scale.

The study’s most consequential finding, however, lies beneath the averages. Pairwise analyses showed that knowledge, attitudes, and practices rose and fell together, with positive correlations significant at P < 0.001. To dissect the architecture of those associations, the researchers deployed structural equation modeling, a statistical framework that combines confirmatory factor analysis with simultaneous regression pathways, allowing investigators to test whether one construct directly influences another while estimating indirect routes through intermediate variables. The fitted model, evaluated with conventional goodness-of-fit indices including the root mean square error of approximation and the standardized root mean square residual, delivered an unambiguous verdict: knowledge exerted a direct positive effect on attitude, with a standardized coefficient of 0.526 at P = 0.007, and attitude exerted a direct positive effect on practice, with a coefficient of 0.516 at P = 0.005. Knowledge, by contrast, showed no statistically significant direct effect on practice. Its influence traveled entirely through attitude, producing a significant indirect effect of 0.271 at P = 0.002. In plain terms, knowing about preoperative radiotherapy does not by itself move a clinician’s hands; it must first move a clinician’s mind.

The survey’s attention to the doctor–patient relationship adds a distinctly human dimension to the statistics. Using the ten-item Difficult Doctor–Patient Relationship Questionnaire, the investigators captured how strained or smooth clinicians find their encounters with patients—a critical variable in oncology, where choosing radiation before surgery requires patients to accept a probabilistic benefit whose costs, in the form of early wound complications, arrive sooner than its rewards. Communication in high-volume orthopedic oncology clinics is shaped by time pressure, uneven health literacy, and the anxiety of families confronting a diagnosis most have never heard of before the day it is delivered. By embedding this relational measure within the same instrument, the authors positioned the clinical encounter itself as part of the machinery through which knowledge becomes practice, acknowledging that even the most confident specialist recommendation must survive a negotiation with a frightened patient weighing surgery, radiation, and the future use of a limb.

The findings land amid a broader recalibration of sarcoma care. Clinical guidance from bodies such as the National Comprehensive Cancer Network and the Chinese Society of Clinical Oncology frames the role of perioperative radiotherapy in high-risk soft tissue sarcoma, and the field is watching the rise of total neoadjuvant therapy—an emerging paradigm in which radiation and systemic treatment are delivered together before surgery, a strategy already reshaping management in other tumor types and now under active scrutiny in sarcoma. Against that backdrop, the variation detected across departments and consultation frequencies reads as a warning about the concentration of expertise: where sarcoma patients are rare, so is the accumulated judgment that converts guidelines into confident action. The authors argue that the response must be systemic—optimizing policies and healthcare services, and directing continuing education not merely at transmitting facts but at cultivating the convictions those facts are meant to produce, because a model in which knowledge acts only through attitude will stall wherever attitude is left unaddressed.

As with any cross-sectional survey, the study captures a single moment and cannot prove the causal direction its elegant statistical fit implies. Purposive sampling concentrated on Beijing hospitals, so the results describe an urban, tertiary-care elite and may not extend to physicians in smaller cities and regional hospitals, where a large share of Chinese patients first seek care. Self-reported practices can diverge from audited clinical behavior, and the questionnaire, while internally consistent, was investigator-designed rather than borrowed wholesale from prior validated instruments. The authors declared no funding and no competing interests, and the paper is being shared early in citable form ahead of final production. These caveats temper, but do not dismantle, the central result, which rests on a large sample, transparent measurement, and a modeling approach whose assumptions can be inspected and retested in other populations.

For patients, the study’s message is easiest to state in anatomical terms: a limb spared, a margin clean, a recurrence avoided—each is more likely when the physicians orchestrating care both understand preoperative radiotherapy and believe in it. What this research demonstrates is that the believing part is not automatic. It is built, measurably, on a foundation of knowledge, and it serves as the engine that converts learning into action. The Beijing team’s quantified pathway from knowledge through attitude to practice offers health systems a map with marked intervention points: strengthen knowledge, and attitudes follow; nurture attitudes, and practice follows. If the goal is care that keeps pace with the best available evidence, the study suggests, medical systems must invest in shaping conviction as deliberately as they invest in disseminating information—an insight that likely extends well beyond sarcoma radiation, to every corner of medicine where guidelines and real-world behavior diverge.